Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1295959 | 0.99 | ITGB3 (0.49) | ITGB3ITGA2BDHODHITGAVCHRM2 | |
| SCHEMBL12103493 | 0.84 | ITGB3 (0.53) | ITGB3ITGA2BDHODHITGAVCHRM2 | |
| Hydrochloric Acid SCHEMBL1296299 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BDHODHITGAVCHRM2 | |
| SCHEMBL10044105 | 0.82 | ITGB3 (0.42) | ITGB3ITGA2B | |
| SCHEMBL1922551 | 0.82 | GPR119 (0.44) | — | |
| SCHEMBL4400790 | 0.82 | MAOA (0.40) | — | |
| SCHEMBL12106777 | 0.81 | ITGB3 (0.41) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13534659 | 0.81 | ITGB3 (0.42) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13534979 | 0.81 | ITGB3 (0.45) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13535046 | 0.81 | ITGB3 (0.41) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| CN-102131778-A | Heterocyclic gpcr agonists | PROSIDION LTD | 2011-07-20 | — | — | CN | disclosed |
| CN-102089301-A | Piperidine gpcr agonists | PROSIDION LTD | 2011-06-08 | — | — | CN | disclosed |
| CN-102083813-A | Piperidinyl gpcr agonists | PROSIDION LTD | 2011-06-01 | — | — | CN | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ITGB3 3442/4885ITGA2B 3353/4885DHODH 3868/4885 |
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | ITGB3 3495/4885ITGA2B 3176/4885DHODH 3770/4885 |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ITGB3 2991/4885ITGA2B 2258/4885DHODH 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.